Glucotrack, Inc. Announces Reverse Stock Split
Glucotrack, Inc. (Nasdaq: GCTK) (Glucotrack or the Company), a healthcare technology and biopharmaceutical company operating Lkahi Therapeutics, today announced that it will effect a 1-for-15 reverse stock split (the Reverse Stock Split) of its issued and outstanding common stock par value $0.001...
Business Wire
Lkahi Therapeutics Initiates Clinical Trial Manufacturing for LT-100
Lkahi Therapeutics Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the Company's lead development candidate for osteoarthritis pain.The advancement of...
Business Wire
Lkahi Therapeutics Expands ai Futures Lab Asset Origination Network Through Continued Collaboration with the University of Georgia
Lkahi Therapeutics, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced the continued participation of the University of Georgias Student Industry Fellows Program in the ai Futures Lab. The renewed collaboration expands Lkahis growing nationwide network of academic institutions...
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers
INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million.
GlucoTrack (NASDAQ:GCTK) shares moved upwards byread more...
Benzinga
Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
Glucotrack, Inc. (Nasdaq: GCTK) today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel has confirmed that Glucotrack has regained compliance with Nasdaq's stockholders' equity...
Business Wire
Glucotrack Announces $5.5 Million Financing
Glucotrack, Inc. (NASDAQ: GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for approximately $5.5 million in financing from participating institutional investors, including a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment in...
Business Wire
Lkahi Therapeutics ai Futures Lab Changes How Biopharma Builds a Pipeline
Glucotrack (NASDAQ: GCTK) today announced the continued expansion of the ai Futures Lab operated through its wholly owned subsidiary, Lkahi Therapeutics Inc. During its first year, the ai Futures Lab identified more than 45 therapeutic opportunities on a budget of approximately $33,000 and advanced...
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers
Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session.
GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap stands atread more...
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers
Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session.
GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding shares is at $1.8read more...
Benzinga
Glucotrack's Lōkahi Unit Pursues Simpler Drug Delivery as LT-100 Moves Toward Its Next Clinical Milestone
Glucotrack (NASDAQ: GCTK) continues to broaden its healthcare platform beyond diabetes technology, announcing a meaningful development for its wholly owned biopharmaceutical subsidiary, Lōkahi Therapeutics, and its lead therapeutic candidate, LT-100. While Glucotrack is widely recognized for developing its long-term implantable continuous blood glucose monitoring (CBGM) system, the company is simultaneously advancing a second growth initiative through Lōkahi, which focuses on acquiring and developing overlooked therapeutic assets.
24-7 Market News